Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mercedeh Ghadessi

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Contemporary Clinical Trials|June 21, 2017
Increasing the efficiency of oncology basket trials using a Bayesian approachRong Liu, Zheyu Liu, Mercedeh Ghadessi, et al.
BMC Genetics|February 3, 2006
A comparison of five methods for selecting tagging single-nucleotide polymorphismsKelly M Burkett, Mercedeh Ghadessi, Brad McNeney, et al.
European Urology|July 7, 2014
Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohortMatthew R Cooperberg, Elai Davicioni, Anamaria Crisan, et al.
Paediatric Drugs|October 14, 2022
Innovations in Clinical Development in Rare Diseases of Children and Adults: Small Populations and/or Small PatientsRobert A Beckman, Zoran Antonijevic, Mercedeh Ghadessi, et al.
Investigative Ophthalmology & Visual Science|July 9, 2024
ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2Robyn H Guymer, Rufino Silva, Mercedeh Ghadessi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|October 4, 2025
Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI StudyKazuhiro Suzuki, Nasreen Khan, Tomoyuki Taguchi, et al.
Prostate Cancer and Prostatic Diseases|March 19, 2026
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT studyNeal D Shore, Daniel J George, Nasreen Khan, et al.
Prostate Cancer and Prostatic Diseases|February 12, 2026
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancerAlicia K Morgans, Christopher J D Wallis, Susan Halabi, et al.
Frontiers in Genetics|February 29, 2012
Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as BiomarkersIsmael A Vergara, Nicholas Erho, Timothy J Triche, et al.
Oncotarget|April 18, 2013
Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study groupKetan Badani, Darby J S Thompson, Christine Buerki, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Contemporary Clinical Trials|June 21, 2017
Increasing the efficiency of oncology basket trials using a Bayesian approachRong Liu, Zheyu Liu, Mercedeh Ghadessi, et al.
BMC Genetics|February 3, 2006
A comparison of five methods for selecting tagging single-nucleotide polymorphismsKelly M Burkett, Mercedeh Ghadessi, Brad McNeney, et al.
European Urology|July 7, 2014
Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohortMatthew R Cooperberg, Elai Davicioni, Anamaria Crisan, et al.
Paediatric Drugs|October 14, 2022
Innovations in Clinical Development in Rare Diseases of Children and Adults: Small Populations and/or Small PatientsRobert A Beckman, Zoran Antonijevic, Mercedeh Ghadessi, et al.
Investigative Ophthalmology & Visual Science|July 9, 2024
ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2Robyn H Guymer, Rufino Silva, Mercedeh Ghadessi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|October 4, 2025
Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI StudyKazuhiro Suzuki, Nasreen Khan, Tomoyuki Taguchi, et al.
Prostate Cancer and Prostatic Diseases|March 19, 2026
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT studyNeal D Shore, Daniel J George, Nasreen Khan, et al.
Prostate Cancer and Prostatic Diseases|February 12, 2026
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancerAlicia K Morgans, Christopher J D Wallis, Susan Halabi, et al.
Frontiers in Genetics|February 29, 2012
Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as BiomarkersIsmael A Vergara, Nicholas Erho, Timothy J Triche, et al.
Oncotarget|April 18, 2013
Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study groupKetan Badani, Darby J S Thompson, Christine Buerki, et al.
Pageof 3